FDA Rejects Aldeyra’s Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns

Louis Velazquez

All NewsApril 3, 2025

The FDA rejected Aldeyra’s resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent